Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
Active, not recruiting · Not applicable · NCT06192758
Conditions: Prostate, Cancer
At a glance
- Research payments reported, 2025
- $271,743
- U.S. investigators named
- 2
- Sites paid
- 3
- Planned or actual enrollment
- 36
About the trial
- Sponsor
- Boston Scientific Corporation
- Tested
- TheraSphere PCa (device)
- Dates
- Started 2024-04-15; completion 2032-10
- Results posted
- Not yet
The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based centers.
From ClinicalTrials.gov, last updated 2026-10-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Boston Scientific Corporation reported $271,743 in research payments for this study in 2025 (10 payments).
Products named: Clinical Trial Product
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Matthew Quirk, M.D. Interventional Radiology · Los Angeles, CA
- Samdeep Mouli, M.D. Interventional Radiology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Northwestern University $265,984
- Ronald Reagan UCLA Medical Center $3,620
- Northwestern Memorial Hospital, IL $2,139
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.